“DogFight” for Control of the Continuous Monitoring Market
News Flash: Abbott Diabetes is apparently “talking tough” about how its new FreeStyle Navigator will quickly become the “device of choice” among us D-types struggling to better manage our disease using constant glucose monitoring. (The Navigator’s expected to win FDA approval by the end of this year). According to the sweeping Reuters story, at least one Morgan Stanley analyst agrees, saying the Navigator trumps the competition on accuracy and ease of use. Hmmph. Hard to say, since hardly anybody’s tried it yet.











